Abcuro, Inc.
Abcuro is a biotechnology company dedicated to developing breakthrough therapies for autoimmune diseases and cancer. Their mission is to precisely modulate cytotoxic T cells to treat serious autoimmune conditions and cancers, including inclusion body myositis, T cell large granular lymphocytic leukemia, and T and NK cell lymphomas. They focus on innovative monoclonal antibodies like ulviprubart that target specific immune cell markers, aiming to deplete pathogenic T cells while sparing protective ones.
Industries
Nr. of Employees
small (1-50)
Abcuro, Inc.
Newton, Massachusetts, United States, North America
Products
Investigational monoclonal antibody targeting KLRG1 (lead clinical candidate)
A clinical-stage monoclonal antibody developed to selectively deplete KLRG1-expressing highly differentiated cytotoxic T cells, intended for treatment of certain autoimmune diseases and T/NK-cell malignancies.
Investigational monoclonal antibody targeting KLRG1 (lead clinical candidate)
A clinical-stage monoclonal antibody developed to selectively deplete KLRG1-expressing highly differentiated cytotoxic T cells, intended for treatment of certain autoimmune diseases and T/NK-cell malignancies.
Expertise Areas
- Clinical trial management (Phase 1–3 and long-term extension studies)
- Pharmacokinetics and pharmacodynamics
- Biologics CMC and process development
- Downstream purification and analytical development
Key Technologies
- Monoclonal antibody therapeutics
- Antibody targeting of inhibitory immune checkpoint receptors
- Radiolabeled PET imaging agents (zirconium-89 tracers)
- Pharmacokinetics / pharmacodynamics analysis